Niagen Bioscience (NAGE) Insider Steven Rubin Buys 31,746 Shares
Insider Steven Rubin acquired 31,746 shares of NAGE on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Steven Rubin bought 31,746 shares of Niagen Bioscience, Inc. ($NAGE) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAGE is down 3.5% after 1 week, down 7.0% after 1 month and down 27.8% to date (from the $3.45 close on Jun 24, 2026).
NAGE
Niagen Bioscience, Inc.
Key Points
- Steven Rubin purchased 31,746 shares of NAGE on June 24, 2026, as part of insider buying activity.
- NAGE shares traded at $3.42 on Saturday, with various institutional investors adjusting their positions.
- Analysts from firms like HC Wainwright & Co. maintained a 'buy' rating with price targets ranging from $10 to $23.
Get $NAGE trade alerts by text
We text you when insiders, Congress or big funds trade $NAGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Niagen Bioscience, Inc. alert may contain errors. Disclosures
Steven Rubin, a notable insider, bought 31,746 shares of NAGE on June 24, 2026. The insider buying was not part of a pre-arranged trading plan. This move indicates a personal investment into the company at a time when the stock traded at $3.42.
Other Institutional Activity in NAGE
Several institutional investors have recently adjusted their positions in NAGE. BlackRock, Inc. reduced its holdings by 204,090 shares, now holding 3,871,619 shares valued at approximately $17,073,839. SteelPeak Wealth, LLC opened a new position, acquiring 3,373,000 shares worth about $14,874,930. Arrowstreet Capital, Limited Partnership increased its stake by 761,685 shares, bringing its total to 2,378,437 shares valued at $10,488,907, marking a 47.1% increase. Vanguard Capital Management LLC also initiated a new position with 2,149,277 shares valued at $9,478,312. Tieton Capital Management, LLC added 384,062 shares, a 23.3% increase, ending with 2,029,155 shares worth around $8,949,000.
Niagen Bioscience, Inc. Stock Up 14.4%
On Saturday, shares of NAGE traded at $3.42. The company has attracted significant attention from institutional investors and insiders alike, with ongoing insider buying and institutional adjustments.
Insider Buying and Selling at Niagen Bioscience, Inc.
On June 24, 2026, several insiders, including Jaksch Frank Jr, Ng Wang Yu Gary, Cohen Ann, Patrick Kristin, Rubin Steven, and Shahbazi Hamed, each purchased 31,746 shares of NAGE. These transactions were not part of any pre-arranged trading plans, indicating personal investment decisions by the insiders.
Analysts Set New Price Targets
Analysts have maintained positive outlooks on NAGE. On May 11, 2026, HC Wainwright & Co. maintained a 'buy' rating with an $11 price target. Canaccord Genuity has consistently maintained its 'buy' rating with targets ranging from $10 to $16 over recent months. Roth Capital also maintained a 'buy' rating with a $23 target as of June 6, 2025.
Bottom Line
The insider buying activity by Steven Rubin and others signals confidence in NAGE's potential. Institutional movements reflect varied strategic positions, while analysts continue to support the stock with 'buy' ratings and significant price targets. As always, 13F filings and insider transactions offer a backward-looking view of investor sentiment and may not reflect current positions.
Related Filing Alerts
Source: Steven Rubin's Form 4 filing on $NAGE (Jun 24, 2026). Find the original filing: NAGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts